Navigation Links
Experimental approach may reverse rheumatoid arthritis and osteoporosis
Date:9/21/2009

Researchers have identified a mechanism that may keep a well known signaling molecule from eroding bone and inflaming joints, according to an early study published online today in the Journal of Clinical Investigation.

Bone is continually recycled to maintain its strength through the competing action of osteoclasts, cells that break down aging bone, and osteoblasts, which build new bone. Osteoclasts also play a central role in common diseases that erode bone, where two signaling molecules, TNFα and RANKL, cause too much bone breakdown. Both are known to turn on the nuclear factor kappa B complex (NF-κB), which turns on genes that cause the stem cell precursors of osteoclasts to mature and start eating bone. While both TNFα and RANKL encourage bone loss, the current study argues that TNFα and RANKL have different effects on levels of a key inhibitory protein within the NF-κB pathway called NF-κB p100, with important consequences for drug design.

The NF-κB pathway as a whole signals for more active osteoclasts, but NF-κB p100 (p100) interferes with the ability of that same pathway to pass on the bone loss signal. While both TNFα and RANKL activate NF-κB signaling, RANKL efficiently converts p100 into a form that no longer blocks NF-κB pathway signaling and that leads to bone loss. In contrast, the current study is the first to show that TNFα lets p100 build up. Thus, TNFα both causes bone loss through NF-κB signaling and limits it via p100 accumulation.

Experiments found further that mice genetically engineered to lack NF-κB2p100 suffered more severe joint erosion and inflammation than their normal littermates in the face of TNFα. TNFα, but not RANKL, also increased levels of a protein in osteoclast precursors called TNF receptor-associated factor 3 (TRAF 3), which may help NF-κB p100 block osteoclast formation and inflammation.


'/>"/>

Contact: Greg Williams
Greg_Williams@urmc.rochester.edu
585-273-1757
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 HealthSciences Institute will ... care professionals, teams and organizations who serve ... chronic diseases in employer, health plan, medical ... collaborative will offer free, noncommercial webinars on ... disease prevention, management and care improvement. Each ...
(Date:12/16/2009)... Trust Sanger Institute announce the first comprehensive analyses of ... mutations in the DNA of cancer cells which are ... malignant melanoma and a lung cancer, reveal for the ... of two cancers. , Lung cancer causes around one ... with smoking. The number of mutations found suggest that ...
(Date:12/16/2009)... Newborn-Safe Skin Care Products from Episencial Offers Planet-Friendly Organics, Solar-Powered ... , ... Los Angeles, CA (PRWEB) ... now have an authentic, affordable choice in all natural skin ... its eponymous product line for young children featuring the beloved ...
(Date:12/16/2009)... leader of Digital Pen and Paper technology and the provider ... today announced that it is ranked among the Fastest Growing ... 2009. , ... (PRWEB) December 16, ... for the capture, digitalization and management of handwritten data. Kayentis ...
(Date:12/16/2009)... 8 percent of children are uninsured, government report finds ... first six months of this year, 45.4 million Americans ... population -- had no health insurance, according to new ... addition, 58.4 million (19.4 percent) people of all ages ... year prior to the interview, and 31.9 million (10.6 ...
Breaking Medicine News(10 mins):Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 2Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 3Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 4Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 5Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2Health News:Over 45 Million Americans Now Lack Health Insurance 2
... The Cystic Fibrosis Foundation reported today that key indicators ... lung function and nutritional status -- are rising nationwide ... the outlook for people with CF continues to improve ... due to quality improvement programs spearheaded by the CF ...
... 28 The newest product offered by,Terumo ... Terumo Interventional Systems announces the launch ... the occlusion of blood,vessels, vascular malformations, and ... embolization system with a hydrogel coating that ...
... 28 The following letter is,being released by CEL-SCI ... Dear Fellow Shareholders:, Our Company underwent a wonderful ... development to a late-stage biotechnology,company. We are now one ... a,completely novel medicine with blockbuster potential ready to go ...
... is the latest American Chemical Society (ACS) News Service Weekly ... & Engineering News.,Please credit the individual journal or the American ... CONTENT IS FOR IMMEDIATE USE EXCEPT ARTICLE #5, which is ... , ARTICLE #1 FOR IMMEDIATE RELEASE ...
... Research Institute (CRI) announced today that it has brought ... Sabin Vaccine Institute, and the Cancer Vaccine Collaborative, a ... Ludwig Institute for Cancer Research (LICR), to form the ... a unified voice in the cancer vaccine field and ...
... 4:30 p.m. Eastern Time -, SAN FRANCISCO, Jan. ... that, based on its end-of-Phase 2 meeting,with the U.S. ... a pivotal confirmatory Phase 3 trial of Dimebon(TM) for,mild-to-moderate ... The FDA informed Medivation that the company,s previously completed,trial ...
Other Medicine News:Health News:Cystic Fibrosis Foundation reports upward trend for key health outcomes 2Health News:Terumo Launches the New AZUR(TM) Peripheral HydroCoil(R) Embolization System with Expanding Hydrogel Technology 2Health News:Terumo Launches the New AZUR(TM) Peripheral HydroCoil(R) Embolization System with Expanding Hydrogel Technology 3Health News:CEL-SCI Corporation Releases Letter to Shareholders 2Health News:American Chemical Society's weekly PressPac -- Jan. 23, 2008 2Health News:American Chemical Society's weekly PressPac -- Jan. 23, 2008 3Health News:American Chemical Society's weekly PressPac -- Jan. 23, 2008 4Health News:American Chemical Society's weekly PressPac -- Jan. 23, 2008 5Health News:American Chemical Society's weekly PressPac -- Jan. 23, 2008 6Health News:American Chemical Society's weekly PressPac -- Jan. 23, 2008 7Health News:American Chemical Society's weekly PressPac -- Jan. 23, 2008 8Health News:American Chemical Society's weekly PressPac -- Jan. 23, 2008 9Health News:American Chemical Society's weekly PressPac -- Jan. 23, 2008 10Health News:Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 2Health News:Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 3Health News:Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimer's Disease in Second Quarter of 2008 2Health News:Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimer's Disease in Second Quarter of 2008 3
(Date:12/16/2009)... 16 Siemens Healthcare today ... to help healthcare ... deadlines defined within the HITECH provision of ... Featuring zero-percent interest terms for ... defer up-front payments associated with their technology ...
(Date:12/16/2009)... -- BioSpecifics Technologies Corp. (Nasdaq: BSTC ), ... products, today announced top-line efficacy and safety results ... for the treatment of Peyronie,s disease. Peyronie,s disease ... on the shaft of the penis, which can ... or impossible in advanced cases. The Phase 2b ...
(Date:12/16/2009)... MAQUET Cardiovascular LLC, a leading ... it has signed a three-year single source ... supply contracting company, for MAQUET,s market-leading VASOVIEW ... products assist healthcare providers in obtaining veins ... only small incisions. This allows for faster ...
Breaking Medicine Technology:Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4New Editor Named for International Journal Of Nursing Terminologies 26amp 3B Classifications 59323 1New Editor Named for International Journal Of Nursing Terminologies 26amp 3B Classifications 59323 2Aon Declares Quarterly Dividend 59320 1Aon Declares Quarterly Dividend 59320 2Hogs n Hens for Hope NCPC BBQ Cook Off 26amp 3B Festival October 17 at Duplin County Events Center Features Fun for the Whole Family and Benefits Laz 59317 1Hogs n Hens for Hope NCPC BBQ Cook Off 26amp 3B Festival October 17 at Duplin County Events Center Features Fun for the Whole Family and Benefits Laz 59317 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: